Blogs

There are four areas of innovation that are noticeable both in isolation and how they feed into each other for a transformation in cancer care “Big data” and Bioinformatics – rapidly developing data management systems and analytics e.g. NGS that will enable us to collect, analyze and learn from vast amounts Continue Reading
 Categories : ASCO17, ASCO18, Disease Area Strategy, Oncology Posted by Preeti Parikh  ,
For more than half a century, patients with Non-Valvular Atrial Fibrillation (NVAF) have been using vitamin K antagonist (Warfarin) to prevent stroke and thromboembolism. Warfarin has proved to be effective, however, it comes with its own baggage of side effects. The use of warfarin is limited due to risk of Continue Reading
 Categories : Competitive Analysis, CV Posted by Preeti Parikh  ,
Biosimilars ASCO 2016
Mylan’s Phase 3 clinical read out was the biosimilar show stopper at ASCO 2016. The biosimilar awareness amongst the attendees was reflected by the full house attendance of biosimilar sessions and presentations throughout the conference. The clinical data from the Phase 3 HERiTAge study, comparing Mylan’s MYL-1401O, potential trastuzumab biosimilar Continue Reading
 Categories : ASCO17, Biosimilars Posted by Richa Agrawal
Biosimilars ASCO 2015
The year 2015 marked the approval of the first biosimilar via the BPCIA pathway in USA. The murmurs of biosimilars could be heard in the corridors of ASCO-2015. A total of 3 clinical read-outs and industry sponsored activities marked the largest oncology congregation of 2015. Russia-based biosimilar developer, Biocad presented Continue Reading
 Categories : ASCO17, Biosimilars Posted by Richa Agrawal
Biopesticides are used for high-quality crop yield for the increasing population and growing organic food demand. Many multinational players have entered into the research and development of biopesticides for diversified crop types. It presents a business opportunity in coming years.       Continue Reading
 Categories : Uncategorized Posted by Richa Agrawal  
China’s Food and Drug Administration has started implementing key reforms that are likely to be a game changer for pharma companies eyeing the Chinese market.  The presentation below highlights the key reforms:     Key Takeaways: Leveling of Phase 1 playing field: Pharma companies can run a phase 1 trial Continue Reading
 Categories : Drug Development, Oncology Posted by Sakshi Saini  ,